<p>CRISPR Therapeutics AG（纳斯达克代码：CRSP - 获取免费报告）首席执行官 Samarth Kulkarni 于 2 月 19 日星期四出售了 6,967 股公司的股票。股票以平均价格 52.58 美元出售，总价值为 366,324.86 美元。出售完成后，首席执行官直接持有 226,106 股公司股票，估值约为 11,888,653.48 美元。这代表其持股比例下降了 2.99%。该交易在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<ul>
<li>CRISPR Therapeutics 在财报发布后上涨，管线希望增加</li>
</ul>
<p>Samarth Kulkarni 最近还进行了以下交易：</p>
<ul>
<li>在 1 月 20 日星期二，Samarth Kulkarni 出售了 30,000 股 CRISPR Therapeutics 的股票。股票以平均价格 51.75 美元出售，总价值为 1,552,500.00 美元。</li>
<li>在 1 月 22 日星期四，Samarth Kulkarni 出售了 60,000 股 CRISPR Therapeutics 的股票。股票以平均价格 60.23 美元出售，总价值为 3,613,800.00 美元。</li>
</ul>
<h2>CRISPR Therapeutics 价格表现</h2>
<p>CRSP 股票在星期五下跌 1.18 美元，跌至 53.46 美元。该股票交易了 1,297,432 股，而其平均交易量为 1,744,686 股。公司的 50 日移动平均线为 53.90 美元，200 日移动平均线为 57.27 美元。CRISPR Therapeutics AG 的 1 年最低价为 30.04 美元，1 年最高价为 78.48 美元。该公司的市值为 51.3 亿美元，市盈率为-8.20，贝塔值为 1.72。</p>
<ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
<p>CRISPR Therapeutics（纳斯达克代码：CRSP - 获取免费报告）最近于 2 月 12 日星期四发布了季度财报。公司报告本季度每股收益（EPS）为-1.37 美元，低于分析师一致预期的-1.15 美元，差距为 0.22 美元。该季度的收入为 86 万美元，而分析师预期为 472 万美元。CRISPR Therapeutics 的股本回报率为-26.31%，净利润率为-16,569.77%。该季度的收入较去年同期下降了 97.8%。在去年同期，该公司每股收益为-1.01 美元。整体来看，股票研究分析师预计 CRISPR Therapeutics AG 今年将发布-5.16 的每股收益。</p>
<h2>CRISPR Therapeutics 的机构交易</h2>
<p>一些机构投资者最近对 CRSP 的持仓进行了调整。ARK Investment Management LLC 在第四季度将其在 CRISPR Therapeutics 的股份增加了 7.5%。ARK Investment Management LLC 目前持有 10,522,057 股公司股票，估值为 551,777,000 美元，此前在该期间内增持了 735,084 股。Orbis Allan Gray Ltd 在第四季度将其在 CRISPR Therapeutics 的股份增加了 19.4%。Orbis Allan Gray Ltd 目前持有 5,950,145 股公司股票，估值为 312,026,000 美元，此前在上个季度增持了 968,060 股。Capital International Investors 在第四季度将其在 CRISPR Therapeutics 的股份增加了 4.3%。Capital International Investors 目前持有 5,892,745 股公司股票，估值为 309,016,000 美元，此前在该期间内增持了 243,487 股。State Street Corp 在第二季度将其在 CRISPR Therapeutics 的股份增加了 35.6%。State Street Corp 目前持有 3,270,596 股公司股票，价值 159,082,000 美元，此前在上个季度增持了 859,334 股。最后，GSK plc 在第四季度收购了 CRISPR Therapeutics 的新股份，估值为 168,890,000 美元。69.20% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>一些券商对 CRSP 发表了评论。Chardan Capital 在 2 月 14 日的研究报告中将 CRISPR Therapeutics 的目标价格从 74.00 美元上调至 76.00 美元，并给予公司 “买入” 评级。Robert W. Baird 在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价格从 52.00 美元下调至 44.00 美元，并给予公司 “中性” 评级。摩根士丹利在周二重申了 “减持” 评级，并将 CRISPR Therapeutics 的目标价格设定为 33.00 美元。加拿大皇家银行在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价格从 42.00 美元上调至 50.00 美元，并给予公司 “行业表现” 评级。最后，Evercore 在 2 月 13 日的报告中重新发布了 “跑赢大盘” 评级，并将 CRISPR Therapeutics 的目标价格设定为 74.00 美元。十位股票研究分析师对该股票给予了 “买入” 评级，六位给予了 “持有” 评级，两位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 64.24 美元。</p>
<p><strong>阅读我们关于 CRSP 的最新研究报告</strong></p>
<h2>CRISPR Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术对人类细胞中的基因进行修改，旨在为一系列严重疾病创造持久的治疗方案。其研发工作集中在体外和体内应用，能够针对性地修正或破坏致病基因。</p>
<p>其主要项目之一是 CTX001，这是一种体外编辑的细胞疗法，旨在治疗镰状细胞病和依赖输血的β-地中海贫血，与 Vertex Pharmaceuticals 合作进行开发。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 CRISPR Therapeutics</li>
<li>免费：可能改变你生活的加密峰会</li>
<li>从安静的复合增长者到 2026 年的突破？BSEM</li>
<li>银价 $309？</li>
<li>Gilder：不要购买 AI 股票，而是这样做</li>
<li>美国的 1776 再次发生</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 CRISPR Therapeutics 吗？</h2>
<p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

CRISPR治疗

IBBQ

<p>CRISPR Therapeutics 首席执行官 Samarth Kulkarni 出售了 6,967 股，售价为每股 52.58 美元，总计 366,324.86 美元，减少了 2.99% 的持股比例。出售后，他持有 226,106 股，估值约为 1189 万美元。此交易已向美国证券交易委员会（SEC）披露。该公司的股票最近交易价格为 53.46 美元，市值为 51.3 亿美元。CRISPR 报告的季度每股收益为（1.37 美元），未达到预期，且收入同比下降 97.8%。机构投资者持有该股票的 69.20%，最近有多家公司的持仓发生了变化</p>

<p>CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 6,967 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the sale, the chief executive officer directly owned 226,106 shares of the company's stock, valued at approximately $11,888,653.48. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG（纳斯达克代码：CRSP - 获取免费报告）首席执行官 Samarth Kulkarni 于 2 月 19 日星期四出售了 6,967 股公司的股票。股票以平均价格 52.58 美元出售，总价值为 366,324.86 美元。出售完成后，首席执行官直接持有 226,106 股公司股票，估值约为 11,888,653.48 美元。这代表其持股比例下降了 2.99%。该交易在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在财报发布后上涨，管线希望增加</li>
</ul>
</div><p>Samarth Kulkarni also recently made the following trade(s):</p>
<div class="lb-trans"><p>Samarth Kulkarni 最近还进行了以下交易：</p>
</div><ul>
<li>On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total value of $1,552,500.00.</li>
<li>On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 20 日星期二，Samarth Kulkarni 出售了 30,000 股 CRISPR Therapeutics 的股票。股票以平均价格 51.75 美元出售，总价值为 1,552,500.00 美元。</li>
<li>在 1 月 22 日星期四，Samarth Kulkarni 出售了 60,000 股 CRISPR Therapeutics 的股票。股票以平均价格 60.23 美元出售，总价值为 3,613,800.00 美元。</li>
</ul>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 价格表现</h2>
</div><p>Shares of CRSP stock traded down $1.18 on Friday, hitting $53.46. 1,297,432 shares of the stock traded hands, compared to its average volume of 1,744,686. The company's fifty day moving average is $53.90 and its 200 day moving average is $57.27. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The company has a market capitalization of $5.13 billion, a PE ratio of -8.20 and a beta of 1.72.</p>
<div class="lb-trans"><p>CRSP 股票在星期五下跌 1.18 美元，跌至 53.46 美元。该股票交易了 1,297,432 股，而其平均交易量为 1,744,686 股。公司的 50 日移动平均线为 53.90 美元，200 日移动平均线为 57.27 美元。CRISPR Therapeutics AG 的 1 年最低价为 30.04 美元，1 年最高价为 78.48 美元。该公司的市值为 51.3 亿美元，市盈率为-8.20，贝塔值为 1.72。</p>
</div><ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business's revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) EPS. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（纳斯达克代码：CRSP - 获取免费报告）最近于 2 月 12 日星期四发布了季度财报。公司报告本季度每股收益（EPS）为-1.37 美元，低于分析师一致预期的-1.15 美元，差距为 0.22 美元。该季度的收入为 86 万美元，而分析师预期为 472 万美元。CRISPR Therapeutics 的股本回报率为-26.31%，净利润率为-16,569.77%。该季度的收入较去年同期下降了 97.8%。在去年同期，该公司每股收益为-1.01 美元。整体来看，股票研究分析师预计 CRISPR Therapeutics AG 今年将发布-5.16 的每股收益。</p>
</div><h2>Institutional Trading of CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in CRSP. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company's stock valued at $551,777,000 after acquiring an additional 735,084 shares during the period. Orbis Allan Gray Ltd boosted its stake in CRISPR Therapeutics by 19.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company's stock valued at $312,026,000 after purchasing an additional 968,060 shares in the last quarter. Capital International Investors increased its position in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company's stock valued at $309,016,000 after purchasing an additional 243,487 shares during the period. State Street Corp raised its stake in shares of CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company's stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter. Finally, GSK plc acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $168,890,000. 69.20% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对 CRSP 的持仓进行了调整。ARK Investment Management LLC 在第四季度将其在 CRISPR Therapeutics 的股份增加了 7.5%。ARK Investment Management LLC 目前持有 10,522,057 股公司股票，估值为 551,777,000 美元，此前在该期间内增持了 735,084 股。Orbis Allan Gray Ltd 在第四季度将其在 CRISPR Therapeutics 的股份增加了 19.4%。Orbis Allan Gray Ltd 目前持有 5,950,145 股公司股票，估值为 312,026,000 美元，此前在上个季度增持了 968,060 股。Capital International Investors 在第四季度将其在 CRISPR Therapeutics 的股份增加了 4.3%。Capital International Investors 目前持有 5,892,745 股公司股票，估值为 309,016,000 美元，此前在该期间内增持了 243,487 股。State Street Corp 在第二季度将其在 CRISPR Therapeutics 的股份增加了 35.6%。State Street Corp 目前持有 3,270,596 股公司股票，价值 159,082,000 美元，此前在上个季度增持了 859,334 股。最后，GSK plc 在第四季度收购了 CRISPR Therapeutics 的新股份，估值为 168,890,000 美元。69.20% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>A number of brokerages have commented on CRSP. Chardan Capital lifted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a &#34;buy&#34; rating in a research note on Saturday, February 14th. Robert W. Baird reduced their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, November 11th. Morgan Stanley restated an &#34;underweight&#34; rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a &#34;sector perform&#34; rating in a research note on Tuesday, November 11th. Finally, Evercore reissued an &#34;outperform&#34; rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $64.24.</p>
<div class="lb-trans"><p>一些券商对 CRSP 发表了评论。Chardan Capital 在 2 月 14 日的研究报告中将 CRISPR Therapeutics 的目标价格从 74.00 美元上调至 76.00 美元，并给予公司 “买入” 评级。Robert W. Baird 在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价格从 52.00 美元下调至 44.00 美元，并给予公司 “中性” 评级。摩根士丹利在周二重申了 “减持” 评级，并将 CRISPR Therapeutics 的目标价格设定为 33.00 美元。加拿大皇家银行在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价格从 42.00 美元上调至 50.00 美元，并给予公司 “行业表现” 评级。最后，Evercore 在 2 月 13 日的报告中重新发布了 “跑赢大盘” 评级，并将 CRISPR Therapeutics 的目标价格设定为 74.00 美元。十位股票研究分析师对该股票给予了 “买入” 评级，六位给予了 “持有” 评级，两位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 64.24 美元。</p>
</div><p><strong>Read Our Latest Research Report on CRSP</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CRSP 的最新研究报告</strong></p>
</div><h2>CRISPR Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术对人类细胞中的基因进行修改，旨在为一系列严重疾病创造持久的治疗方案。其研发工作集中在体外和体内应用，能够针对性地修正或破坏致病基因。</p>
</div><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p>
<div class="lb-trans"><p>其主要项目之一是 CTX001，这是一种体外编辑的细胞疗法，旨在治疗镰状细胞病和依赖输血的β-地中海贫血，与 Vertex Pharmaceuticals 合作进行开发。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>From Quiet Compounder to 2026 Breakout? BSEM</li>
<li>Silver $309?</li>
<li>Gilder: Don’t Buy AI Stocks, Do This Instead</li>
<li>America’s 1776 happening again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 CRISPR Therapeutics</li>
<li>免费：可能改变你生活的加密峰会</li>
<li>从安静的复合增长者到 2026 年的突破？BSEM</li>
<li>银价 $309？</li>
<li>Gilder：不要购买 AI 股票，而是这样做</li>
<li>美国的 1776 再次发生</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CRISPR Therapeutics（纳斯达克代码：CRSP）的首席执行官出售了价值 366,324.86 美元的股票